Personalized antibiotic treatment for older adults
This study tests whether giving the antibiotic ceftazidime-avibactam in a personalized way, based on your body's ability to process the drug, works better for adults 60 and older with serious infections. The goal is to improve treatment outcomes and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 60 years of age or older.
- You must be scheduled to receive the antibiotic ceftazidime-avibactam (also called Avycaz) for more than 5 days.
- You must not have taken ceftazidime-avibactam within the past month.
- You cannot be on dialysis (hemodialysis, peritoneal dialysis, or continuous renal replacement therapy).
- You cannot have a history of kidney removal, kidney transplant, having only one kidney, or uremia (kidney failure).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This study tests an antibiotic called ceftazidime-avibactam for people with serious infections like bloodstream infections or pneumonia that started in the hospital or from a breathing machine. It aims to start treatment quickly after identifying the bacteria.
This study tests whether tailoring the dose of the antibiotic ceftobiprole based on your individual body and kidney function helps treat infections more safely and effectively in older adults.
This trial tests whether measuring drug levels in the blood can help doctors give the right dose of ceftazidime-avibactam (an antibiotic) to patients with hard-to-treat infections in the ICU, potentially improving treatment outcomes and reducing side effects.
This study looks at how a certain antibiotic (ceftazidime-avibactam) works in people with blood cancers or stem cell transplants, and how the drug levels affect the bacteria. It aims to find the best dosing to fight infections and reduce resistance.
This trial tests a specific antibiotic combination (ceftazidime-avibactam) in patients with serious infections that are resistant to other antibiotics, while they are in intensive care. The goal is to see how well this treatment works for critically ill patients.
Hear when a new Ceftazidime-avibactam trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.